Clifton Flack from CIITECH, a UK-Israel cannabis biotech startup, spoke to reporters about the funding they are putting forward to further the all-important research.
Speaking to reporters, Flack said, “Israel is the epicenter of R&D on cannabis and most of the work has happened in the Hebrew University. Asthma is close to my heart as I suffer from the condition.”
Initially, the study will look to see whether CBD, a compound in cannabis, has an inhibitory effect on allergic airway inflammations that cause asthma.
The good news is, that CBD is non-psychoactive, meaning that it doesn’t make the patient feel high or spaced out, but can help to alleviate a variety of medical conditions and issues.
In speaking about the exciting new research study, Prof. Mechoulam said, “We know that CBD has anti-inflammatory properties and we’re looking forward to investigating whether this will be effective in treating asthma and related respiratory conditions.”
Mechoulam’s Colleague for the study, Prof. Francesca Levi-Schaffer, is also very excited about the prospect of this forthcoming study. Her lab focuses on discovering new ways to treat allergies.
Reporters also caught up with Prof. Levi-Schaffer, “Most of the symptoms of allergic disease patients are controlled by either symptomatic drugs or corticosteroids. However, some patients are steroid-resistant and allergic diseases such as severe asthma have been labeled as unmet clinical needs.” She added, “We believe our research will provide a novel and effective solution to treating this condition.”
The new study is being met with much anticipation, as previously researchers at the Hebrew University have proved that CBD can work effectively in some cases to treat epilepsy, schizophrenia and pain, among other ailments.
For the time being, Flack is also excited about the study, “We hope to have preliminary results of the research in some six months.” noting that, “Cannabis could well become this century’s wonder drug,” concluding, “Many of the plant’s therapeutic benefits and compounds are yet to be explored and we’re excited to take part in expanding and galvanizing this new field of therapy.”
This study highlights that the UK and Israel are at the forefront of cannabinoid science as it relates to a treatment for Asthma.
Respiratory conditions such as COPD and Asthma are conditions that relate to inflammation.
It’s a condition that affects over 5 million people in Britain, and therefore there is a vital need for studies that can lead to awareness of the potential for therapeutic cannabis as a treatment for sufferers.
The Hebrew University of Jerusalem in Israel together with CIITECH are positioning themselves to be at the forefront of this health sector.